Come and meet Sistemic at Stand 4 to learn about our first-in-class miRNA assay SistemPSCCheckTM for detection of residual PSCs in derived cell therapies.
We would love to talk to you about how we can support you in the development of your stem cell therapy products
Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217
The European Patent Office communicated its decision to grant European Patent No. EP2609217, in the name of Sistemic Scotland Ltd titled “Cell Characterisation”.
The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.
SistemPSCCheck™ is a first-in-class miRNA-based assay, for high sensitivity assessment of residual undifferentiated PSCs in derived cell preparations. SistemPSCCheck™ is a safety and batch release assay service to support the clinical and commercial development of pluripotent stem cell-derived cell therapy products.
SistemPSCCheck™ was developed in conjunction with National Measurement Laboratory for Chemical and Bio-Measurement at LGC and was supported by the UK’s innovation agency, Innovate UK, under the “Analysis for Innovators” grant.
